DOI: 10.1002/ccr3.4481

### CASE REPORT

Clinical Case Reports

Open Access WILEY

# Infectious-mononucleosis-like exanthema associated with COVID-19 in a child

Meryam Ferjani<sup>1,2</sup> | Malek Ben Slimane<sup>2,3</sup> | Taha Sayari<sup>1,2</sup> | Yosra Hammi<sup>1,2</sup> | Noureddine Litaiem<sup>2,3</sup> | Ouns Naija<sup>1,2</sup> | Faten Zeglaoui<sup>2,3</sup> | Tahar Gargah<sup>1,2</sup>

<sup>1</sup>Pediatry Department, Charles Nicolle Hospital, Tunis, Tunisia

<sup>2</sup>Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia

<sup>3</sup>Dermatology Department, Charles Nicolle hospital, Tunis, Tunisia

#### Correspondence

Malek Ben Slimane, Charles Nicolle hospital, Tunis, Tunisia, 50798509. Email: benslimanemalek1990@gmail. com

Funding information None

# **1** | INTRODUCTION

A three-year-old girl presented with a 3-day history of fevers and sore throat. She was put on amoxicillin. Five days later, she developed a maculopapular morbilliform exanthema. A nasopharyngeal swab confirms the COVID-19 diagnosis. Skin manifestations of childhood COVID-19 are not specific and could be mistaken with other viral exanthema.

The Coronavirus Disease 2019 (COVID-19) is less common in young children than in adults. Childhood COVID-19 differs from adulthood COVID-19 in terms of clinical presentation, course, and outcomes. The clinical course of COVID-19 is mild in most affected children.<sup>1</sup> Fever and cough are the most commonly reported symptoms in children with COVID-19.<sup>2</sup> Cutaneous manifestations of childhood COVID-19 are various.<sup>3</sup> Herein, we report an infectious-mononucleosis-like exanthema as a possible COVID-19–associated skin manifestation in a child.

#### Abstract

Cutaneous manifestations of childhood COVID-19 differ from those of adults. Maculopapular rash is not specific and could be mistaken with other viral exanthema. A nasopharyngeal swab is strongly recommended to confirm the possible COVID-19 diagnosis.

KEYWORDS children, COVID-19, skin

# 2 | CASE REPORT

A three-year-old girl presented with a 3-day history of continuous fevers greater than 38.5°C and sore throat. She was previously fit and well. Her past medical history was unremarkable. Her mother had a headache and diarrhea lasting a week. Clinical examination revealed pseudomembranous angina. The child was put on amoxicillin. Fever lasted five more days, and she developed a skin eruption. On examination, she was systemically well with normal vital signs. She was still feverish and had a generalized maculopapular morbilliform exanthema (Figures 1 and 2). Nikolsky sign was negative. No mucosal involvement was noted. Infectious mononucleosis (IM) was suspected. We performed serologic tests of Epstein-Barr virus (EBV). IgM and IgG antibodies to the viral capsid antigen and antibodies to the nuclear antigen were not detected. Viral tests for cytomegalovirus and parvovirus B19 were negative. The patient was examined by our colleagues at the National Pharmacovigilace center. The role of amoxicilline was excluded. Patch tests were programed

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2021 The Authors. *Clinical Case Reports* published by John Wiley & Sons Ltd.

WILEY Clinical Case Reports

later. Routine blood tests, including complete blood count and liver transaminases, showed no abnormalities. C-reactive protein (CRP) level was elevated (160 mg/L). The patient had a nasopharyngeal swab to test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using reverse transcription-polymerase chain reaction, which was positive. Due to prolonged fever, exanthema and biological inflammatory syndrome, pediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS) was suspected. The patient immediately received a dose of 2 g/kg of intravenous immunoglobulin. Other investigations including troponin T, procalcitonin, ferritin, D-Dimer, fibrinogen, lactate, triacylglycerol, chest X-ray, and echocardiography were normal. After one dose of immunoglobulin, fever and exanthema disappeared and no complementary treatments were needed.

# 3 | DISCUSSION

We reported a case of maculopapular rash in a child leading to the diagnosis of COVID-19. To the best of our knowledge, there are less than ten cases of maculopapular rash in pediatric COVID-19 reported in the literature.

Skin disease of COVID-19 could be seen in 20.4% of adults.<sup>4</sup> It can be divided into two main clinical patterns: inflammatory lesions (exanthema, chicken pox-like vesicles, and urticaria) and vascular lesions (purpura and livedo).<sup>5</sup> Cutaneous manifestations of childhood COVID-19 differ from those of adults. Erythema multiform, chilblain, and Kawasaki-like multisystemic inflammatory syndrome in children or PIMS-TS are more frequently seen in children.<sup>3,6,7</sup> Maculopapular rash, very often in adults, is uncommon in the pediatric COVID-19.5 Bursal Duramaz B et al<sup>8</sup> reported maculopapular rashes and erythematous eruptions in three pediatric patients. The rash was itchy in two patients. It had a similar appearance to the rash of roseola in one patient. Sze May Ng described a maculopapular rash in a 12-year-old boy following recovery of COVID-19, 4 weeks after diagnosis.<sup>9</sup> In our patient, we did not perform a skin biopsy. Histological feature of maculopapular eruption in children is superficial perivascular dermatitis with slight exocytosis, swollen thrombosed vessels with neutrophils, eosinophils, and nuclear debris.<sup>10,11</sup> Maculopapular exanthema in COVID-19 children lasted generally less than 1 week. It could resolve with no complications and without specific treatment.<sup>12</sup> There is not any correlation between the exacerbation of the rash and the disease's severity.8



FIGURE 1 maculopapular morbliform exanthema on the trunk



**FIGURE 2** maculopapular morbiliform exanthema on the lower limbs

II FY

Differential diagnosis of pediatric exanthema is numerous including drug reaction and viral eruption. Genovese G et al presented case of COVID-19-associated varicellalike exanthema in an 8-year-old girl with mild systemic symptoms. Varicella infection was unlikely based on prior infection and the absence of mucosal involvement as well as pruritus.<sup>13</sup> In our patient, the exanthema occurred 5 days after an erythematous angina treated with amoxicillin. These findings suggest the diagnosis of IM secondary to an active EBV replication. A hypersensitivity skin reaction could be seen in the course of IM because of amoxicillin administration. It could be explained by the decreased tolerance of the immune system of patients with IM and/or the enhancement of immune reaction to certain drugs or its metabolites.<sup>14</sup> Typically, it manifests by fever, pharyngitis, and lymphadenopathy. The cutaneous manifestations of IM include a morbilliform exanthema located first on the trunk and upper extremities. The diagnosis of IM usually relies on serologic tests.<sup>15</sup> To the best of our knowledge, there is no case reported in the literature of a rash in COVID-19 patient induced by penicillins. In our patient, we believe that treatment with amoxicillin and the development of this COVID-19-related rash are coincidental.

In conclusion, clinical course of COVID-19 infection in children is mild and the diagnosis could be misdiagnosed. Skin manifestations such as maculopapular rash are not specific and could be mistaken with other viral exanthema. In this time of global pandemic and in order to break the chain of transmission immediately, we would strongly recommend a nasopharyngeal swab to confirm the possible COVID-19 diagnosis.

## ACKNOWLEDGEMENTS

Published with written consent of the patient.

CONFLICT OF INTEREST None.

## AUTHOR CONTRIBUTIONS

Drs Malek Ben Slimane, Maryem Ferjani, and Nourredine Litaiem contributed to the first draft of the manuscript. Drs Malek Ben Slimane, Meriem Ferjani, Nourredine Litaiem, Taha Sayari, Yousra Hammi, and Ouns Naija contributed to the literature search, analysis, and interpretation of the data. Dr Taher Gargah and Dr Faten Zeglaoui critically revised the manuscript and gave final approval. All authors read and approved the final manuscript and agree to be finally accountable for ensuring the integrity of and accuracy of the work.

## ETHICS STATEMENT

Consent for publication has been obtained.

## DATA AVAILABILITY STATEMENT

The data that support the findings of this article are available from the corresponding author upon reasonable request.

#### REFERENCES

- Lu X, Zhang L, Du H, et al. Chinese pediatric novel coronavirus study team. SARS-CoV-2 infection in children. *N Engl J Med*. 2020;382(17):1663-1665.
- She J, Liu L, Liu W. COVID-19 epidemic: disease characteristics in children. J Med Virol. 2020;92(7):747-754.
- 3. Andina D, Belloni-Fortina A, Bodemer C, et al. ESPD Group for the Skin Manifestations of COVID-19. Skin manifestations of COVID-19 in children: part 1. *Clin Exp Dermatol*. 2021;46(3):444-450.
- Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34(5):e212-e213.
- Wollina U, Karadağ AS, Rowland-Payne C, Chiriac A, Lotti T. Cutaneous signs in COVID-19 patients: a review. *Dermatol Ther*. 2020;33(5):e13549.
- Felsenstein S, Willis E, Lythgoe H, et al. Presentation, treatment response and short-term outcomes in paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS). J Clin Med. 2020;9(10):3293.
- Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. *BMJ*. 2020;369:m2094.
- Bursal Duramaz B, Yozgat CY, Yozgat Y, Turel O. Appearance of skin rash in pediatric patients with COVID-19: three case presentations. *Dermatol Ther*. 2020;33(4):e13594.
- Ng SM. Prolonged dermatological manifestation 4 weeks following recovery of COVID-19 in a child. *BMJ Case Rep.* 2020;13(8):e237056.
- Andina D, Belloni-Fortina A, Bodemer C, et al. ESPD group for the skin manifestations of COVID-19. Skin manifestations of COVID-19 in children: part 3. *Clin Exp Dermatol.* 2021;46:462-472. https://doi.org/10.1111/ced.14483
- Colmenero I, Santonja C, Alonso-Riano M, et al. SARS COV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of 7 paediatric patients. *Br J Dermatol.* 2020;183:729-737.
- Morey-Olivé M, Espiau M, Mercadal-Hally M, Lera-Carballo E, García-Patos V. Cutaneous manifestations in the current pandemic of coronavirus infection disease (COVID 2019). *An Pediatr (Engl Ed)*. 2020;92(6):374-375.
- Genovese G, Colonna C, Marzano AV. Varicella-like exanthem associated with COVID-19 in an 8-year-old girl: a diagnostic clue? *Pediatr Dermatol.* 2020;37(3):435-436.
- Jappe U. Amoxicillin-induced exanthema in patients with infectious mononucleosis: allergy or transient immunostimulation? *Allergy*. 2007;62(12):1474-1475.
- 15. Di Lernia V, Mansouri Y. Epstein-Barr virus and skin manifestations in childhood. *Int J Dermatol*. 2013;52(10):1177-1184.

How to cite this article: Ferjani M, Ben Slimane M, Sayari T, et al. Infectious-mononucleosis-like exanthema associated with COVID-19 in a child. *Clin Case Rep.* 2021;9:e04481. <u>https://doi.org/10.1002/</u> <u>ccr3.4481</u>